Structure Therapeutics is trading 4.1% higher at $51.50 in pre-market, continuing a strong rebound driven by a broader biotech rally and improving risk appetite for growth stocks.
- The stock maintains its upward momentum after closing 4.5% higher at $49.47 on July 30.
- Gains are largely tied to sector-wide strength in healthcare names, as no new company-specific catalysts have been reported.